View Older Stories View More Recent Stories

Sep 22, 2026 08:31AM Incyte to present skin disease data at EADV congress in Vienna
Sep 16, 2026 09:33AM Incyte (INCY) Reiterated at Neutral by Cantor Fitzgerald as Opzelura Attractive in HS
Sep 11, 2026 07:24AM Incyte (INCY) Reiterated at Neutral by Cantor Fitzgerald After Management Chat
Sep 1, 2026 07:12AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Sep 1, 2026 04:02AM BMO Capital Reiterates Market Perform Rating on Incyte (INCY)
Aug 27, 2026 07:06AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Aug 20, 2026 07:16AM Canaccord Starts Incyte (INCY) at Buy
Aug 20, 2026 06:52AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Aug 3, 2026 06:54AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Jul 29, 2026 07:19AM Incyte (INCY) PT Raised to $150 at Guggenheim
Jul 29, 2026 06:54AM Incyte (INCY) PT Raised to $150 at H.C. Wainwright
Jul 29, 2026 06:01AM EU approves Incyte's Opzelura cream for moderate atopic dermatitis
Jul 28, 2026 01:38PM Incyte (INCY) PT Raised to $120 at Oppenheimer
Jul 28, 2026 07:04AM Incyte (INCY) Tops Q2 EPS by 110c ; Offers Guidance
Jul 21, 2026 06:51AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Jul 17, 2026 01:11PM Incyte to present six oncology studies at ESMO Congress 2026
Jul 15, 2026 04:37AM Incyte (INCY) Reiterated at Market Perform by Citizens on Updated VIVID-3 Data
Jul 14, 2026 06:57AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Jul 13, 2026 07:58AM Incyte (INCY) PT Raised to $112 at BMO Capital
Jun 29, 2026 07:10AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Jun 26, 2026 09:56AM Incyte (INCY) PT Raised to $113 at UBS
Jun 24, 2026 06:43AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Jun 22, 2026 01:26PM Incyte (INCY) PT Raised to $105 at Truist Securities
Jun 22, 2026 07:53AM Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
Jun 22, 2026 04:19AM BMO Capital Upgrades Incyte (INCY) to Market Perform
Jun 15, 2026 10:10AM BMO Capital on Incyte (INCY): ''989 Updates Provide More Context to ET/MF Opportunity'
Jun 15, 2026 09:24AM Stifel Reiterates Buy Rating on Incyte (INCY)
Jun 10, 2026 04:39PM Incyte (INCY) PT Raised to $136 at Guggenheim
Jun 10, 2026 07:11AM Incyte (INCY) PT Raised to $140 at H.C. Wainwright
Jun 9, 2026 09:11AM Stifel Reiterates Buy Rating on Incyte (INCY)
Jun 8, 2026 02:49PM Incyte (INCY) PT Raised to $107 at Oppenheimer
Jun 4, 2026 08:06AM Mirum and Incyte to present zilurgisertib study results at ENDO 2026
Jun 2, 2026 04:37AM Incyte (INCY) Reiterated at Market Perform by Citizens Amid Positive Trial Results
Jun 1, 2026 07:34AM Incyte (INCY) Reiterated at Buy by Stifel
Jun 1, 2026 06:56AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Jun 1, 2026 02:53AM Incyte drug combination reduces lymphoma progression risk by 25%
May 21, 2026 04:39PM Bernstein SocGen Group Starts Incyte (INCY) at Market Perform
May 21, 2026 06:38AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Apr 29, 2026 10:15AM Incyte (INCY) PT Raised to $123 at Stifel Following 'Solid' Q1 Results
Apr 29, 2026 07:15AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Apr 28, 2026 04:32PM Incyte (INCY) PT Raised to $90 at Oppenheimer
Apr 28, 2026 03:10PM Incyte (INCY) PT Raised to $103 at Morgan Stanley
Apr 28, 2026 02:52PM Incyte (INCY) PT Raised to $124 at TD Cowen
Apr 28, 2026 07:06AM Incyte (INCY) Tops Q1 EPS by 46c; offers guidance
Apr 23, 2026 05:48AM MINJUVI approved in Australia for relapsed follicular lymphoma treatment
Apr 15, 2026 07:18AM H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
Apr 2, 2026 07:01AM Adagene partners with Incyte for cancer drug combination study
Apr 2, 2026 05:07AM Incyte (INCY) Reiterated at Market Perform by Citizens- 'Shares are Fairly Valued'
Mar 30, 2026 10:19AM William Blair on Incyte (INCY): 'encouraged' by Ph3 data and deepened responses
Mar 30, 2026 07:42AM Incyte (INCY) Reiterated at Buy by Stifel on Constructive View for Povorcitinib
View More Recent Stories View Older Stories